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Objective To collect and analyze data on susceptibility of methicillin-resistant staphylococci to
evernimicin and other antimicrobial agents.
Methods Recent clinical isolates of methicillin-resistant staphylococci from 33 laboratories in North
America, Europe and South Africawere investigated.
Results Of the antimicrobial agents tested, evernimicin had the lowestMIC90s formethicillin-resistant
Staphylococcus aureus andmethicillin-resistant coagulase-negative staphylococci (0.75 and1.0mg/L,
respectively). Resistance to cipro£oxacin and erythromycinwas widespread, with higher levels of resistance
inNorth America than in other regions.
Conclusions Susceptibility surveys help to determine the antimicrobial activity of new agents.
Cipro£oxacin- and erythromycin-resistant staphylococciwere prevalent throughout all regions.
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I N T R O D U C T I O N
Despite advances in anti-infective therapy over the past two
decades, the incidence of multiresistant Gram-positive infec-
tions continues to increase. Among the most problematic
pathogens are Staphylococcus aureus and methicillin-resistant
coagulase-negative staphylococci (MR-CNS), such as Staphy-
lococcus epidermidis.The resistance of staphylococci to antibio-
tics, particularly those used for ¢rst-line therapy, is a cause for
concern.
At highest risk of developing methicillin-resistant Staphylo-
coccus aureus (MRSA) infections, one of the major causes of
nosocomial morbidity and mortality, are patients in intensive
care units, burns units, the elderly, the very young, and those
with a compromised immune system. MRSA infections are
highly prevalent in central and southern Europe [1], and their
prevalence appears to be increasing [2,3].
Among antibiotics, co-resistance to penicillin, erythromy-
cin, cipro£oxacin and gentamicin is common in MRSA. In
the USA, a retrospective analysis of susceptibility results for
MRSA from1989 to 1992 demonstrated that the level of resis-
tance to cipro£oxacin was as high as 80% [4]. Recently, there
have been the ¢rst reports of vancomycin-resistant MRSA in
Japan [5,6] and the USA [7]. Vancomycin and teicoplanin
(other than in the USA) are the principal antimicrobial agents
of last resort. Increased use of these glycopeptides in the
empirical treatment and prophylaxis of MRSA infections can
only hasten the development of resistance to this class of anti-
microbial agent [8,9].
MR-CNS are some of the most common causative agents
in nosocomial blood infections.Widespread methicillin resis-
tance has emerged among these pathogens, particularly
among Staphylococcus epidermidis and Staphylococcus haemolyticus
[10,11]. Furthermore, recent studies have indicated widespread
resistance to the quinolones, particularly cipro£oxacin, in
MR-CNS. Increasing resistance rates to erythromycin have
also been reported [11,12].
Tolerance and occasional resistance to vancomycin and tei-
coplanin in MR-CNS have been detected more commonly,
particularly among Staphylococcus haemolyticus [13^16].
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As a result of these emerging resistance patterns, and in
addition to the implementation of strategies to combat further
development of vancomycin resistance, novel antibiotics to
combat staphylococcal bacteremias are urgently required.
The in vitro activity of evernimicin against Gram-positive
pathogens has been shown to be consistently greater than that
of vancomycin against the same isolates [17]. Evernimicin has
a unique site of action andworks by binding to the 50s subunit
of the bacterial ribosome, thereby inhibiting protein synth-
esis. Mutants have been characterized in the rpl16 gene and in
the unique arm of the 23s rRNA, suggesting binding at the
junction of the 23s rRNA and the rpl16 gene.There is no cross-
resistance with any other antibiotics currently used in
humans.
The aim of the present study was to collect data on suscept-
ibility of recent Gram-positive organisms to evernimicin and
other selected antimicrobial agents.
M ET H O D S
In total, 33 laboratories (11 in North America, 21 in Europe
or Turkey, and one in South Africa) were asked to contribute
50 recently isolated clinical strains of MRSA or MR-CNS.
Organisms were identi¢ed to the species level by the routine
methods of each laboratory. In certain instances, speciation
was not possible, and these organisms were recorded as methi-
cillin-resistant staphylococci. In certain centers, where the col-
lection of MRSA strains was problematic, the collection of a
smaller number of staphylococcal isolates was permitted.
Susceptibility testing
Susceptibility testing of isolates was performed by the E-test
method for cipro£oxacin, oxacillin, dalfopristin/quinupris-
tin, erythromycin, evernimicin and vancomycin. An 80%
inhibition endpoint was utilized for evernimicin, as recom-
mended by the manufacturer (data on ¢le, ABBiodisk, Solna,
Sweden).The presence of a ceftizoxime disk in addition to the
oxacillin E-test strip aided the identi¢cation of MRSA and
MR-CNS in the absence of salt-containing agar.The method
and interpretive criteria for each antimicrobial tested were as
recommended by the National Committee for Clinical
Laboratory Standards [18,19] (see Table1 for antimicrobial
breakpoints).There is good correlation between the E-test and
NCCLSmethodologies [20,21].
The proposed susceptibility criteria for evernimicin were
based on previously published pharmacokinetic studies [22^
24]. For each laboratory, if the geometric mean exceeded that
of the total study population by four-fold or more in either
direction, the results were excluded from the analysis. It was
requested that isolates with evernimicin MIC values above
prespeci¢ed levels (2mg/L for MRSA/MR-CNS) be sent to
the Department of Pathology, University of Iowa College of
Medicine, Iowa City, Iowa, for further characterization.
To provide uniformityof susceptibility testing, each labora-
tory was asked to provide three replicates of MIC data on sup-
plied ATCC organisms (Enterococcus faecalis ATCC 29212;
Staphylococcus aureus ATCC 29213, and Streptococcus pneumoniae
ATCC 49619). North American sites were also asked to pro-
vide data on seven challenge organisms (two staphylococci,
Table 1 Overall susceptibility of MRSA and MR-CNS
Organism (no. tested)
% by categorya
Antimicrobial agent MIC50 (mg/L) MIC90 (mg/L) Range Susceptible Resistant
MRSA (765)
Evernimicin 0.25 0.75 0.032±3.0 100.0 0.0
Quinupristin/dalfopristin 0.75 1.5 0.125 to >32 82.6 0.7
Vancomycin 1.5 2 0.25±4 100.0 0.0
Cipro¯oxacin > 32 >32 0.094 to >32 20.9 79.1
Erythromycin > 256 >256 0.016 to >256 11.2 86.9
Oxacillin > 256 >256 0.5 to >256 1.8 98.2
MR-CNSb (688)
Evernimicin 0.5 1 0.016±6 99.9 0.1
Quinupristin/dalfopristin 0.38 1 0.064 to >32 92.3 1.2
Vancomycin 2 3 0.19±256 99.1 0.1
Cipro¯oxacin 3 >32 0.047 to >32 47.5 52.5
Erythromycin > 256 >256 0.016 to >256 27.8 70.6
Oxacillin 256 >256 0.125 to >256 1.6 98.4
aNCCLS susceptibility criteria; bMR-CNS, methicillin-resistant coagulase-negative staphylococci. Proposed susceptibility criteria for
evernimicin: R4 mg/L, susceptible; r16 mg/L, resistant.
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three enterococci, and two streptococci) to highlight potential
methodology problems. To pass the quality control stage and
proceed to the collection and testing of clinical isolates, each
laboratory had to score 90% accuracyor higher.
R E S U L TS
In total, 765 strains of MRSA and 688 strains of MR-CNS
were collected and tested at 29 of the 33 participating labora-
tories. Not all laboratories identi¢ed all isolates to the species
level. Consequently, the MR-CNS group included 122 strains
of Staphylococcus spp. and121 strains of CNS in addition to 425
strains of Staphylococcus epidermidis, six strains of Staphylococcus
haemolyticus, seven strains of Staphylococcus hominis, ¢ve strains
of Staphylococcus saprophyticus, and two strains of Staphylococcus
warnerii.
Data from two laboratories were eliminated from the sur-
vey because they failed to reach the 90% accuracy threshold
speci¢ed in the study protocol. Data from a further two
laboratories were excluded from the ¢nal analysis because the
laboratory evernimicin geometric mean MICwas either four-
fold higher or four-fold lower than the all-site geometric
meanMIC forMRSA/MR-CNS (Figure1).
The distribution of MICs for MRSA and MR-CNS is
shown in Figure 2 and follows a similar bell-shaped curve for
both groups of organisms, with the pattern for MR-CNS
being displaced to the right (higherMICs).
Repeat evernimicin MICs were performed on 23 of 49
MRSA/MR-CNS isolates initially classed as outliers. Four-
Figure 1 Laboratory variation in geometric mean MIC90 values for evernimicin in MRSA and MR-CNS.
Figure 2 Histogram of evernimicin population versus MRSA
and MR-CNS.
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teen of these 23 isolates were from the USA, eight from Swe-
den and one from the Czech Republic. All retested isolates
were found to be fully susceptible to evernimicin (MICR 2
mg/L). In most instances, the discrepancy arose as a result of
di¤culty in reading the 80% inhibition breakpoint. Although
the remaining outliers were not available for retesting, they
were left in the database.
Antimicrobial susceptibilities of MRSA and MR-CNS
MIC50 and MIC90 values for MRSA and MR-CNS for all
study antibiotics are displayed in Table1, with sensitivity
breakpoints shown inTable 2.
Evernimicin had the lowest MIC values of all the study
antimicrobial agents, with MIC90s of 0.75 and 1.0mg/L
againstMRSA andMR-CNS, respectively.
There was some evidence of resistance to the quinupristin/
dalfopristin combination. In general, resistance to quinupris-
tin/dalfopristin was more prevalent in the MR-CNS strains
(0^3.9%) than inMRSA (0^2.7%). In total, 13 isolates (four in
Turkey, three in the Czech Republic, two in France, and one
each in Denmark, Russia, Sweden and North America) were
resistant to quinupristin/dalfopristin (¢ve MRSA, eight MR-
CNS). All 13 strains were fully susceptible to evernimicin and
vancomycin, six were susceptible to cipro£oxacin, one was
susceptible to erythromycin, and all were resistant to oxacillin
and ceftizoxime.
Analysis of the susceptibility of MRSA and MR-CNS
strains according to the geographic distribution of study cen-
ters showed that the activity of evernimicin was maintained
throughout all regions studied (Table 3). Quinupristin/dalfo-
pristin-resistant MRSA strains were seen in central, eastern,
southern and western Europe. Quinupristin/dalfopristin
resistance was also seen in MR-CNS, but to a lesser extent
than in MRSA. High levels (> 25%) of MRSA intermediate
resistancewere seen inNorth America and northern Europe.
MRSA and MR-CNS resistance to erythromycin and
cipro£oxacin was widespread throughout Europe, North
America and South Africa. Erythromycin resistance was more
prevalent than cipro£oxacin resistance in MR-CNS, except in
western Europe, and in MRSA in central and eastern Europe
and South Africa.
The rate of co-resistance to cipro£oxacin and erythromycin
was lowest in eastern Europe (e.g. Russia, Poland and Bul-
garia), and centers located in the south of the USA (Houston
andNewOrleans).
Vancomycin-intermediate and -resistant staphylococci
There was little evidence of vancomycin resistance, but exam-
ination of the range of MIC90 values revealed the presence of
several MRSA/MR-CNS strains with MIC90 values r8mg/
L at sites in central Europe.
Five strains with intermediate resistance to vancomycin
were recorded in this study (one in Bulgaria, two in the Czech
Republic, and two in Denmark). All were MR-CNS and sus-
ceptible to evernimicin and quinupristin/dalfopristin.
One unspeciated, methicillin-resistant staphylococcal strain
isolated in Finland was susceptible to evernimicin and quinu-
pristin/dalfopristin and resistant to all other tested antimicro-
bial agents.
D IS C U S S IO N
MRSA and MR-CNS infections are an increasing cause of
nosocomial morbidity and mortality worldwide. The emer-
gence of co-resistance to other commonly used `¢rst-line'
antibiotics, such as cipro£oxacin, erythromycin and gentami-
cin, in these bacteria is a growing concern and probably
re£ects the global overuse of these antibiotics in the past.
While bacterial resistance to the agents of `last resort', the
glycopeptides, remains infrequent and isolated among the sta-
phylococci [5^7,25], the recent emergence of glycopeptide
Table 2 Sensitivity breakpointsa for MRSA and MR-CNS
MRSA MR-CNS
Susceptible Intermediate Resistant Susceptible Resistant
Quinupristin/dalfopristin R 1 2 r 4 ± ±
Vancomycin R 4 8±16 r 32 ± ±
Cipro¯oxacin R 1 2 r 4 ± ±
Erythromycin R 0.5 1±4 r 8 ± ±
Oxacillin R 2 ± r 3 R 0.25 r 0.38
aValues represent mg/L.
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resistance among other Gram-positive bacteria (e.g. vancomy-
cin-resistant enterococci) suggests that, in time, glycopeptide-
resistant staphylococciwill also develop [8,9].
There is therefore a need for an antimicrobial agent with
high activity against MRSA and MR-CNS. Several such new
antibacterial agents are currently undergoing rapid clinical
development.
This study was designed to evaluate the global susceptibil-
ity of evernimicin, a novel oligosaccharide antibiotic, against
MRSA and MR-CNS, in comparison with other commonly
used `¢rst-line'antibiotics (cipro£oxacin and erythromycin), a
new streptogramin combination (quinupristin/dalfopristin),
and vancomycin.The design of the studyalso permitted analy-
sis of emerging trends of resistance and co-resistance to these
antibiotics throughout North America, Europe and South
Africa.
The E-test methodwas used to test antibiotic susceptibility.
In general, the E-test method proved to be reliable and pro-
duced results of comparable accuracy to those obtained using
more conventional methodology.Therewas some interlabora-
tory variation in geometric mean MIC values for evernimicin
determined using the E-test, caused by di¡use endpoints.
However, on retesting, all strains were susceptible to everni-
micin. Similar problems in reading endpoints have been
encountered for quinupristin/dalfopristin, particularly during
susceptibility testing of pneumococci.
The results of this study demonstrated that of all the anti-
biotics tested, evernimicin had the lowest MIC values (MIC90
R 1.0mg/L for MRSA and MR-CNS). There was no evi-
dence of resistance to evernimicin in strains isolated from any
study center, suggesting that evernimicin may be a suitable
alternative to vancomycin for the treatment of staphylococcal
infections.
While the new streptogramin combination, quinupristin/
dalfopristin, was highly e¡ective against both MRSA and
MR-CNS, therewas already some evidence of emerging resis-
tance to this compound, particularly at surveillance centers in
Europe.
Cipro£oxacin- and erythromycin-resistant MRSA and
MR-CNSwere prevalent throughout all regions.These results
re£ect the extensive use of macrolides in North America and
quinolones within Europe. Consistent with these results is the
recent report of the European Study Group on Antibiotic
Resistance (ESGAR) showing an increase in resistance to
cipro£oxacin in staphylococci from southern Europe [1].
Overall, the results of this study underscore the utility of
broad-based geographic surveys in monitoring trends in anti-
microbial susceptibility. Such programs can be especially
helpful in screening the antimicrobial activity of new agents
such as evernimicin.
C O N C L U SI O N
In this study, evernimicin was active against all isolated strains
and, on the basis of these results, is likely to be a suitable alter-
native to vancomycin for the treatment of infections caused by
methicillin-resistant staphylococci.
U P D A T E
During the publication review process for this manuscript,
an analysis of phase II/III clinical trials failed to show su¤cient
advantage over existing products in the treatment of vanco-
mycin-susceptible and -resistant Gram-positive infections.
Schering-Plough has halted the clinical development of ever-
nimicin.
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